Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Solid Tumor
Interventions: Sirolimus, Cyclophosphamide, Etoposide, Celecoxib; Drug
Lead sponsor: Emory University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more

Conditions: Acute Coronary Syndrome
Interventions: Clopidogrel, Prasugrel, Commercially-available Aspirin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 9,326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 165
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 162 more

Conditions: Perianal Crohn's Disease
Interventions: BLI-1300 low dose, BLI-1300 high dose, placebo; Drug
Lead sponsor: Braintree Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 17
States / cities: Anaheim, California • San Francisco, California • Jacksonville, Florida + 14 more

Conditions: Post Surgical Neuropathic Pain
Interventions: Qutenza (capsaicin) 8% topical system, capsaicin 0.04% topical system; Drug
Lead sponsor: Averitas Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 23
States / cities: Tucson, Arizona • Vista, California • Washington D.C., District of Columbia + 19 more

Conditions: Breast Cancer
Interventions: DS-8201a; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 36
States / cities: Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 26 more

Conditions: Substance Use Disorders, Substance Abuse, Substance Use, Substance Dependence
Interventions: The Bridge; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Alzheimer's Disease
Interventions: Placebo Capsule(s) Once a Day by Mouth, Nilotinib Capsule(s) Once a Day by Mouth; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Atherosclerosis Cardiovascular Disease, ASCVD, ASCVD Management
Interventions: ABP-745 Dose A, Placebo, ABP-745 Dose B, ABP-745 Dose C; Drug
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Beverly Hills, California • San Diego, California • Torrance, California + 1 more

Conditions: Venous Thrombosis Deep (Limbs), Surgical Blood Loss
Interventions: Enoxaparin Injectable Product, Sodium chloride; Drug
Lead sponsor: Valleywise Health; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Dentine Hypersensitivity, Dental Pain
Interventions: 5% calcium sodium phosphosilicate toothpaste, 7.5% calcium sodium phosphosilicate toothpaste, Placebo toothpaste; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Juvenile Myelomonocytic Leukemia
Interventions: Vorinostat, Azacitidine Injection; Drug
Lead sponsor: Johns Hopkins All Children's Hospital; Other
Eligibility: 1 Year to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Pancreatic Cancer
Interventions: Intravenous Vitamin C, Gemcitabine; Drug
Lead sponsor: Jeanne Drisko, MD, CNS, FACN; Other
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Prostate Cancer
Interventions: Radiation, MRI, Androgen Deprivation Therapy; Radiation · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer, Urothelial Carcinoma
Interventions: Trastuzumab deruxtecan, Nivolumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Santa Monica, California • New Haven, Connecticut • Miami, Florida + 7 more

Conditions: Hereditary Inclusion Body Myopathy (HIBM)
Interventions: Sialic Acid Extended Release (SA-ER) Tablets, Sialic Acid Extended Release (SA-ER) Tables; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Costa Mesa, California • New York, New York

Conditions: HIV Infections
Interventions: Interferon alfa-n3, Interferon alfa-n1; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 15
States / cities: Los Angeles, California • Redwood City, California • New Haven, Connecticut + 9 more

Conditions: Multiple Myeloma
Interventions: Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone; Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 3 more

Conditions: Complex Regional Pain Syndrome, Chronic Pain, Causalgia, Complex Regional Pain Syndrome Type I, Complex Regional Pain Syndrome Type II
Interventions: Low dose naltrexone, Placebo sugar capsules; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure, Congestive
Interventions: Furosemide, Torsemide, Bumetanide, sacubitril/valsartan, Hydralazine, Isosorbide Dinitrate; Drug
Lead sponsor: Heart Center Research, LLC; Network
Eligibility: 19 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Hypertension
Interventions: Lisinopril; Drug
Lead sponsor: Uptal Patel; Other
Eligibility: 2 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more

Conditions: Seborrheic Keratosis
Interventions: A-101 Vehicle, A-101 (40) Topical Solution, A-101 (32.5) Topical Solution; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 5
States / cities: Snellville, Georgia • Clinton Township, Michigan • Portland, Oregon + 2 more

Conditions: Sickle Cell Disease
Interventions: ketamine; Drug
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 7 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Farmington, Connecticut • Hartford, Connecticut

Conditions: Anemia Associated With Chronic Kidney Disease (CKD)
Interventions: Vadadustat, Mircera®; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 58
States / cities: Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more

Conditions: Preeclampsia, Aspirin, Clinical Decision Support Systems, Economics, Behavioral
Interventions: Electronic health record best practice alert; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: Female only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Danville, Pennsylvania

Search by objective public record fields.

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease

Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis

Pre-operative Enoxaparin in the Surgical Management of Multi-trauma Patients Undergoing Orthopedic Surgical Procedures

Dose Response of a Tubule Occlusion Agent

Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

New Treatment Option for Pancreatic Cancer

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Low-Dose Ketamine Infusion for Children With Sickle Cell Disease-Related Pain

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Low Dose Aspirin Alerts in High-Risk Pregnancies